BioSpace News Archive

Gilero, a contract design, development and manufacturing firm specializing in medical and drug delivery devices, has announced the opening of a new Design Center in Carlsbad, California

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug Administration (FDA) that Reblozyl (luspatercept-aamt) will not be reviewed at the Oncologic Drugs Advisory Committee (“ODAC”) meeting scheduled for December 18, 2019.

Proton Therapy Partners (PTP) is pleased to announce the addition of David L. Bernd to its Board of Directors.

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired shares of Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) from March 27, 2019 to November 8, 2019, inclusive (the “Class Period”).

The Mental Health Commission of Canada and the Canadian Centre on Substance Use and Addiction applaud the federal government for putting mental health and addiction squarely on the map in its December 5th throne speech.

Kodiak Sciences Inc. (Nasdaq: KOD), today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a price to the public of $46.00 per share.

Almac scientists to develop novel manufacturing process for essential medicine